
FDA Warning ‘Bombshell’ Caps Top JIA Developments for 2024
For juvenile idiopathic arthritis (JIA), 2024 was marked by both successes and heightened controversy. There were new US Food and Drug Administration (FDA) warnings for DRESS (drug reaction with eosinophilia and systemic symptoms) in patients receiving …